title: Comparison of the approaches to non-febrile neutropenia developing in children with acute lymphoblastic leukemia.
abstract: The objectives of this study was to investigate of the influences of high-dose (20 mg/kg/day) methyl prednisolone (HDMP) and granulocyte colony stimulating factor (G-CSF) in shortening the duration of chemotherapy-induced neutropenia encountered in children with ALL receiving maintenance therapy. Sixty-four non-febrile neutropenic attacks developed in 29 patients with ALL receiving St Jude XIII maintenance protocol were evaluated retrospectively. The patients were clinically followed up without drugs for shortening the duration of neutropenia in 21 (32.8%) attacs, while HDMP and G-CSF were administered in 26 (40.6%) and 17 (26.6%) attacks, respectively. After the detection of neutropenia, restoration of neutrophil counts at 2nd or 4th days to the levels that allow resuming the chemotherapy were considered as success. While second day and overall success rates in patients administered HDMP and G-CSF were significantly higher than the patients who were observed clinically. Both second day and overall neutrophil counts were significantly higher in patients administered G-CSF than the other groups. Methyl prednisolone and G-CSF treatments were well-tolerated by the patients. The cost-per neutropenic attack was significantly higher in G-CSF group than of the HDMP group. Especially in patients experiencing frequent neutropenic attacks and hence interruptions of the therapy, one of the myelopoiesis induction therapies can be used to shorten the duration of neutropenia. For this indication short-course HDMP therapy can be considered as an alternative to G-CSF in this patients due to its relatively low cost, amenability to outpatient administration, and well-tolerability by children.
authors.affiliation: Department of Pediatrics, Ondokuz Mayis University, Samsun, Turkey. sukrupaksu@yahoo.com
authors.forename: Muhammet Sukru
authors.initials: MS
authors.lastname: Paksu
authors.forename: Sule
authors.initials: S
authors.lastname: Paksu
authors.forename: Mehtap
authors.initials: M
authors.lastname: Akbalik
authors.forename: Emel
authors.initials: E
authors.lastname: Ozyurek
authors.forename: Feride
authors.initials: F
authors.lastname: Duru
authors.forename: Davut
authors.initials: D
authors.lastname: Albayrak
authors.forename: Tunc
authors.initials: T
authors.lastname: Fisgin
mesh_terms: D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D002648:Child; D002675:Child, Preschool; D005260:Female; D005334:Fever; D005500:Follow-Up Studies; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use*; D009503:Neutropenia / Q000097:blood / Q000139:chemically induced / Q000188:drug therapy*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000097:blood / Q000188:drug therapy*; D012189:Retrospective Studies
chemical_list: D016179:Granulocyte Colony-Stimulating Factor; D008775:Methylprednisolone